Antimicrobial Dosing in Acute Renal Replacement

Advances in Chronic Kidney Disease

Volumn 20, Issue 1, 2013, Pages 85-93

  Fissell, William H ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Acute kidney injury; Antimicrobial agents; Continuous renal replacement therapy; Hemodialysis; Sustained low efficiency dialysis

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; CASPOFUNGIN; CEFTRIAXONE; CIPROFLOXACIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; MEROPENEM; NYSTATIN; PENICILLIN DERIVATIVE; PIPERACILLIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; CONTINUOUS RENAL REPLACEMENT THERAPY; DIALYSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; REVIEW;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CRITICAL CARE; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; PIPERACILLIN; PRACTICE GUIDELINES AS TOPIC; RENAL REPLACEMENT THERAPY; TISSUE DISTRIBUTION;

EID: 84871550172     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.10.004     Document Type: Review

References (77)

1. Hsu C.Y., Vittinghoff E., Lin F., Shlipak M.G. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004, 141(2):95-101. [see comment].
2. VA/NIH Acute Renal Failure Trial Network Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008, 359(1):7-20.
3. Bellomo R., Cass A., Cole L., et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009, 361(17):1627-1638. RENAL Replacement Therapy Study Group Investigators.
4. Ronco C., Bellomo R., Homel P., et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000, 356(9223):26-30. [see comment].
5. Bouman C.S., Oudemans-Van Straaten H.M., Tijssen J.G., et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 2002, 30(10):2205-2211.
6. Cornejo R., Downey P., Castro R., et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006, 32(5):713-722.
7. Lorenzen J.M., Broll M., Kaever V., et al. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol 2012, 7(3):385-390.
8. Seyler L., Cotton F., Taccone F.S., et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15:R137.
9. Roberts J.A., Kruger P., Paterson D.L., Lipman J. Antibiotic resistance-what's dosing got to do with it?. Crit Care Med 2008, 36(8):2433-2440.
10. Bauer S.R., Salem C.A., Connor M.J., et al. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol 2012, 7:452-457.
11. Clark J.A., Coopersmith C.M. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007, 28(4):384-393.
12. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011, 66(suppl 2):ii25-ii31.
13. Goncalves-Pereira J., Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011, 15(5):R206. Epub 2011 Sep 13.
14. Neuner E.A., Ahrens C.L., Groszek J.J., et al. Use of therapeutic drug monitoring to treat Elizabethkingia meningoseptica meningitis and bacteraemia in an adult. J Antimicrob Chemother 2012, 67(6):1558-1560. Epub 2012 Feb 22.
15. Swartz R.D., Messana J.M. Simultaneous catheter removal and replacement in peritoneal dialysis infections: update and current recommendations. Adv Perit Dial 1999, 15:205-208.
16. von Winckelmann S.L., Spriet I., Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy 2008, 28(11):1391-1400.
17. Klotz U., Teml A., Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007, 46(8):645-660.
18. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7(11):1748-1756.
19. Baxter Healthcare Cyclophosphamide for Injection, USP 2007, Baxter Healthcare Corporation, Deerfield, IL.
20. Bedford L. Vinblastine Sulfate for Injection USP 2001, Bedford Laboratories, Bedford, OH.
21. Daunorubicin Prescribing Information 1999, Ben Venue Laboratories I, Bedford Laboratories, Bedford, OH.
22. den Hartigh J., McVie J.G., van Oort W.J., Pinedo H.M. Pharmacokinetics of mitomycin C in humans. Cancer Res 1983, 43(10):5017-5021.
23. Hassan M., öberg G., Ehrsson H., et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989, 36:525-530.
24. Pinguet F., Culine S., Bressolle F., et al. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Clin Cancer Res 2000, 6(1):57-63.
25. Rengelshausen J., Hull W.E., Schwenger V., Goggelmann C., Walter-Sack I., Bommer J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 2002, 39(2):E10.
26. Stewart C.F. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994, 34(suppl):S76-S83.
27. Takeuchi M., Yamauchi T., Yoshida I., et al. Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis. Int J Hematol 2003, 77(2):196-198.
28. Yoshida H., Goto M., Honda A., et al. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Cancer Chemother Pharmacol 1994, 33(6):450-454.
29. Roberts J.A., Roberts M.S., Robertson T.A., Dalley A.J., Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration?. Crit Care Med 2009, 37:926-933.
30. van Zanten A.R., Polderman K.H., van Geijlswijk I.M., et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008, 23(3):422-430.
31. Zeitlinger M.A., Erovic B.M., Sauermann R., Georgopoulos A., Muller M., Joukhadar C. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother 2005, 56(4):703-708.
32. Gulyassy P.F., Jarrard E., Stanfel L.A. Contributions of hippurate, indoxyl sulfate, and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans. Biochem Pharmacol 1987, 36(24):4215-4220.
33. Igarashi P., Gulyassy P., Stanfel L., Depner T. Plasma hippurate in renal failure: high-performance liquid chromatography method and clinical application. Nephron 1987, 47(4):290-294.
34. Butterfield J.M., Patel N., Pai M.P., Rosano T.G., Drusano G.L., Lodise T.P. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother 2011, 55(9):4277-4282. Epub 2011 June 13.
35. Roberts J.A., Taccone F.S., Udy A.A., Vincent J.L., Jacobs F., Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011, 55(6):2704-2709. Epub 2011 Mar 14.
36. Vilay A.M., Churchwell M.D., Mueller B.A. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care 2008, 12:235-244.
37. Michaud J., Nolin T.D., Naud J., et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008, 108:157-163. Epub 2008 Oct 9.
38. Tiranathanagul K., Yossundharakul C., Techawathanawanna N., et al. Comparison of middle-molecule clearance between convective control double high-flux hemodiafiltration and on-line hemodiafiltration. Int J Artif Organs 2007, 30(12):1090-1097.
39. Messer J., Mulcahy B., Fissell W.H. Middle-molecule clearance in CRRT: in-vitro convection, diffusion, and dialyzer area. ASAIO J 2009, 55(3):224-226.
40. Bunchman T.E., Valentini R.P., Gardner J., Mottes T., Kudelka T., Maxvold N.J. Treatment of vancomycin overdose using high-efficiency dialysis membranes. Pediatr Nephrol 1999, 13(9):773-774.
41. Lemaire M., Connolly B., Harvey E., Licht C. Treatment of paediatric vancomycin intoxication: a case report and review of the literature. NDT Plus 2010, 3(3):260-264.
42. Schliamser S.E., Cars O., Norrby S.R. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrobial Chemother 1991, 27(4):405-425.
43. Ferguson M.A., Waikar S.S. Established and emerging markers of kidney function. Clin Chem 2012, 58(4):680-689. Epub 2012 Feb 6.
44. Wang E., Sandoval R.M., Campos S.B., Molitoris B.A. Rapid diagnosis and quantification of acute kidney injury using fluorescent ratio-metric determination of glomerular filtration rate in the rat. Am J Physiol Renal Physiol 2010, 299(5):F1048-F1055. Epub 2010 Aug 4.
45. Cruz D.N., Ricci Z., Ronco C. Clinical review: RIFLE and AKIN-time for reappraisal. Crit Care 2009, 13(3):211. Epub 2009 Jun 25.
46. Bouchard J., Macedo E., Soroko S., et al. Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. Nephrol Dial Transpl 2010, 25(1):102-107. Epub 2009 Aug 13.
47. Demirjian S., Poggio E.D. Critical care: estimating renal function in the ICU: even more challenging. Nat Rev Nephrol 2011, 7(10):549-550.
48. Matsushita K., Mahmoodi B.K., Woodward M., et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012, 307(18):1941-1951.
49. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-RR212. Acute Dialysis Quality Initiative Workgroup.
50. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11(2):R31.
51. Pickering J.W., Frampton C.M., Walker R.J., Shaw G.M., Endre Z.H. Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care 2012, 16(3):R107.
52. Aronoff G.R., Bennett W.M., Berns J.S., et al. Drug Prescribing in Renal Failure 2007, American College of Physicians, Philadelphia, PA. 5th ed.
53. Bogard K.N., Peterson N.T., Plumb T.J., Erwin M.W., Fuller P.D., Olsen K.M. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 2011, 39(3):560-570.
54. Trotman R.L., Williamson J.C., Shoemaker D.M., Salzer W.L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005, 41:1159-1166.
55. Valtonen M., Tiula E., Takkunen O., Backman J.T., Neuvonen P.J. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001, 48:881-885.
56. Arzuaga A., Maynar J., Gascon A.R., et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005, 45:168-176.
57. Mueller S.C., Majcher-Peszynska J., Hickstein H., et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002, 46:1557-1560.
58. Joukhadar C.M.D., Frossard M.M.D., Mayer B.X.P., et al. Impaired target site penetration of [beta] -lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29:385-391.
59. Sadaba B., Azanza J.R., Campanero M.A., Garcia-Quetglas E. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome. Clin Microbiol Infect 2004, 10:990-998.
60. Boselli E., Breilh D., Rimmelé T., et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008, 36:1500-1506.
61. Varghese J.M., Roberts J.A., Lipman J. Pharmacokinetics and pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol 2010, 23:472-478.
62. Aronoff G.R., Berns J.S., Brier M.E., et al. Drug Prescribing in Renal Failure 1999, American College of Physicians, Philadelphia, PA. 4th ed.
63. Sauermann R., Zeitlinger M., Erovic B.M., et al. Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model. Int J Antimicrob Agents 2003, 22:574-578.
64. Shea K.M., Cheatham S.C., Wack M.F., et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2009, 34:429-433.
65. Van Bambeke F., Tulkens P.M. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001, 18:S17-S23.
66. Decker B.S., Mohamed A.N., Chambers M., Kraus M.A., Moe S.M., Sowinski K.M. Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis. Am J Nephrol 2012, 36:144-150. Epub 2012 July 18.
67. Wright D.H., Brown G.H., Peterson M.L., Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000, 46:669-683.
68. Agwuh K.N., MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006, 58:256-265.
69. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006, 42(suppl 1):S35-S39.
70. Begic D., von Eiff C., Tsuji B.T. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype. J Antimicrob Chemother 2009, 63:977-981. Epub 2009 Mar 19.
71. Groll A.H., Piscitelli S.C., Walsh T.J. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001, 21(8 Pt 2):133S-148S.
72. Baddley J.W., Patel M., Bhavnani S.M., Moser S.A., Andes D.R. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008, 52:3022-3028. Epub 2008 Jun 30.
73. Andes D., Marchillo K., Conklin R., et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004, 48:137-142.
74. Antachopoulos C., Meletiadis J., Sein T., Roilides E., Walsh T.J. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008, 52:321-328. Epub 2007 Oct 15.
75. Joos B., Schmidli M., Keusch G. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant 1996, 11(8):1582-1585.
76. van der Werf T.S., Mulder P.O., Zijlstra J.G., Uges D.R., Stegeman C.A. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997, 23(8):873-877.
77. Capellier G.M.D., Cornette C.P., Boillot A.M.D., et al. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 1998, 26(1):88-91.